COMMUNIQUÉS West-GlobeNewswire
-
DBV Technologies intégrera l’Indice Euronext Tech Leaders
23/06/2026 -
'Possibilities' Premieres June 27, Reimagining Accessible Filmmaking Through Collaboration Between Blind, Low-Vision, and Sighted Creatives
23/06/2026 -
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
23/06/2026 -
Nyxoah Organisera une Journée Investisseurs à New York le 8 juillet 2026
23/06/2026 -
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
23/06/2026 -
Nyxoah to Host Investor Day in New York on July 8, 2026
23/06/2026 -
FitRx Expands Online Weight-Management Program With Needle-Free Oral Semaglutide Option
23/06/2026 -
MSK Masters Announces Release of Sonography of the Extremities - Techniques and Protocols, 5th Edition
23/06/2026 -
Zealthy Expands Insurance Coordination for GLP-1 Weight-Loss Medications
23/06/2026 -
Biocodex Microbiota Foundation invites Canadian academics and scientists to apply for €35,000 ($55,000 CAD based on current exchange rate) research grant to advance microbiota research in human health & disease
23/06/2026 -
Premier Health of America Obtains Creditor Protection Under The CCAA-Operations to Continue Without Interruption
23/06/2026 -
SK pharmteco lance SKyvec™, une plateforme unifiée de vecteurs viraux à haut rendement destinée à accélérer le développement des thérapies géniques, de la fabrication au patient
23/06/2026 -
Zealthy Launches Enhanced Weight-Loss Care Platform With Integrated Zepbound Access and Insurance Support
23/06/2026 -
Clever Care Health Plan Adds Veteran Medical, Economics, and Population Health Experts to Leadership Team After Reaching 51,000 Members
23/06/2026 -
GENFIT : Données positives de Phase 1b obtenues avec GNS561 en combinaison, dans une population de patients atteints de cholangiocarcinome lourdement prétraités
23/06/2026 -
Clariane announces the success of its offering of €333 million of hybrid notes
23/06/2026 -
GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
23/06/2026 -
Clariane annonce le succès de son offre de 333 millions d’euros d’obligations hybrides
23/06/2026 -
TogetherTuesday: Arizona Nonprofit Surpasses $6 Million for Childhood Blindness Research
23/06/2026
Pages